

#15-1

PTO/SB/08A (04-03)  
Approved for use through 04/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Page 1 of 3

## Complete if Known

Application Number	09/769,223
Filing Date	January 24, 2001
First Named Inventor	Raoul E. BENVENISTE
Art Unit	1648
Examiner Name	Jeffrey S. Parkin
Attorney Docket Number	015280-196310US

## U.S. PATENT DOCUMENTS

Examiner	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code <sup>2</sup> (if known)			
	AA	US-5,256,767	10/26/1993	Salk et al.	
	AB	US-5,480,967	01/02/1996	McMichael et al.	

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	AC	WO	91/13910	A1	09/19/1991	The United States of America as represented by The Secretary, U.S. Department of Commerce		


Examiner Signature		Date Considered	10/31/03
-----------------------	--	--------------------	----------

\*EXAMINER: Initial if reference, considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page 2 of 3

## **Complete if Known**

Application Number	09/769,223
Filing Dat	January 24, 2001
First Named Inventor	Raoul E. BENVENISTE
Art Unit	1648
Examiner Name	Jeffrey S. Parkin
Attorney Docket Number	015280-196310US

## **NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AD	Chakerian <i>et al.</i> , 1994, "Persistence of simian immunodeficiency virus Mne variants upon transmission," <i>J. Virol.</i> 68(6):4080-4085 (Abstract)	
	AE	Du <i>et al.</i> , 1996, "Requirements for lymphocyte activation by unusual strains of simian immunodeficiency virus," <i>J. Virol.</i> 70(6):4157-4151 (Abstract)	
	AF	Eriksson <i>et al.</i> , 1993, "Systematic identification of T-cell activating epitopes on the human immunodeficiency virus type 1 envelope glycoprotein gp120 in primates immunized with synthetic peptides," <i>Vaccine</i> 11(8):859-865 (Abstract)	
	AG	Gorelick <i>et al.</i> , 2000, "Mucosal challenge of <i>Macaca nemestrina</i> with simian immunodeficiency virus (SIV) following SIV nucleocapsid mutant DNA vaccination," <i>J. Med. Primatol</i> 29:209-219	
	AH	Gorelick <i>et al.</i> , 2000, "Protection of <i>Macaca nemestrina</i> from disease following pathogenic simian immunodeficiency virus (SIV) challenge: Utilization of SIV nucleocapsid mutant DNA vaccines with and without an SIV protein boost," <i>Journal of Virology</i> 74(24):11935-11949	
	AI	Javaherian <i>et al.</i> , 1992, "The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 89(4):1418-1422 (Abstract)	
	AJ	Joag <i>et al.</i> , 1997, "Animal model of mucosally transmitted human immunodeficiency virus type 1 disease: intravaginal and oral deposition of simian/human immunodeficiency virus in macaques results in systemic infection, elimination of CD4+ T cells, and AIDS," <i>J. Virol.</i> 71(5):4016-4023 (Abstract)	
	AK	Johnston and Flores, 2001, "Progress in HIV vaccine development," <i>Current Opinion in Pharmacology</i> 1:504-510	
	AL	Kaul <i>et al.</i> , 2000, "HIV-1-specific mucosal CD8 <sup>+</sup> lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi," <i>The Journal of Immunology</i> 164:1602-1611	
	AM	Newman <i>et al.</i> , 1992, "Immunogenicity and toxicity testing of an experimental HIV-1 vaccine in nonhuman primates," <i>AIDS Res. Hum. Retroviruses</i> 8(8):1413-1418 (Abstract)	
	AN	"NIH aid, monkey research provide good news in quest for AIDS vaccine, but big obstacles persist," <i>Biotechnology News</i> 17(1):5-6	
	AO	Polacino <i>et al.</i> , 1999, "Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in macaques," <i>Journal of Virology</i> 73(10):8201-8215	
	AP	Rowland-Jones <i>et al.</i> , 1998, "Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi," <i>J. Clin. Invest.</i> 102(9):1758-1765	
	AQ	Steger and Pauza, 1997, "Immunization of <i>Macaca mulatto</i> with aroA attenuated <i>Salmonella typhimurium</i> expressing the SIVp27 antigen," <i>J. Med. Primatol.</i> 26(1-2):44-50 (Abstract)	


Examiner  
SignatureDate  
Considered

10/31/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



#15-3

PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**


(use as many sheets as necessary)

Page 3 of 3

**Complete if Known**

Application Number	09/769,223
Filing Date	January 24, 2001
First Named Inventor	Raoul E. BENVENISTE
Art Unit	1648
Examiner Name	Jeffrey S. Parkin
Attorney Docket Number	015280-196310US

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AR	Wyand <i>et al.</i> , 1997, "Resistance of neonatal monkeys to live attenuated vaccine strain of simian immunodeficiency virus," <i>Nat. Med.</i> 3(1):32-36 (Abstract)	
	AS	"HIV Vaccine Development Status Report, May 2000" Available Website: <a href="http://www.niaid.nih.gov/d aids/vaccine/whsummarystatus.htm">www.niaid.nih.gov/d aids/vaccine/whsummarystatus.htm</a> Last update: August 6, 2001 Accessed on: June 30, 2003	

Examiner Signature		Date Considered	10/31/03
-----------------------	---	--------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.